Download PDF
Semin Thromb Hemost 2002; 28(1): 19-28
DOI: 10.1055/s-2002-20561
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Coagulation System as a Target for the Treatment of Human Gliomas

Deborah L. Ornstein1 , Kenneth R. Meehan2 , Leo R. Zacharski3
  • 1Director, Special Hematology and Coagulation Laboratory, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas and Uniformed Services University of the Health Sciences, Bethesda, Maryland
  • 2Section Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire and Dartmouth Medical School, Hanover, New Hampshire
  • 3Veterans Administration Medical Center, White River Junction, Vermont and Dartmouth Medical School, Hanover, New Hampshire
Further Information

Publication History

Publication Date:
05 March 2002 (online)

    Permissions and Reprints

ABSTRACT

Coagulation activation in human gliomas may have two consequences: (1) activation of systemic coagulation reactions leading to the development of venous thromboembolic disease, and (2) stimulation of tumor growth and invasion. Anticoagulation in patients with gliomas, therefore, may not only prevent thrombosis but also have anticancer activity. Tissue factor and thrombin are appropriate targets for intervention, and several drugs are suitable for testing. Low-molecular-weight heparin and direct thrombin inhibitors are useful for reducing thrombin production and activity, and recombinant tissue factor pathway inhibitor and statins are examples of drugs that target tissue factor directly. This article reviews the implications of coagulation activation in human gliomas and provides a rationale for clinical testing of anticoagulants as part of a treatment strategy for this devastating human cancer.

KEYWORD

Glioma - tissue factor - coagulation - lovastatin - anticoagulants

REFERENCES

  • 1 Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer statistics, 2001.  CA Cancer J Clin . 2001;  51 15-36
    CrossrefPubMedGoogle Scholar
  • 2 DeAngelis L. Brain tumors.  N Engl J Med . 2001;  344 114-123
    CrossrefPubMedGoogle Scholar
  • 3 Marras L, Geerts W, Perry J. The risk of venous thromboembolism is increased throughout the course of malignant glioma.  Cancer . 2000;  89 640-646
    CrossrefPubMedGoogle Scholar
  • 4 Bjorklid E, Storm-Mathisen J, Storm E, Prydz H. Localization of tissue thromboplastin in the human brain.  Thromb Haemost . 1997;  37 91-97
    PubMedGoogle Scholar
  • 5 Hamada K, Kuratsu J, Saitoh Y. Expression of tissue factor in glioma.  Brain Tumor Pathol . 1996;  13 115-118
    Google Scholar
  • 6 Hamada K, Kuratsu J, Saitoh Y. Expression of tissue factor correlates with grade of malignancy in human glioma.  Cancer . 1996;  77 1877-1883
    CrossrefPubMedGoogle Scholar
  • 7 Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, αvβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.  Br J Cancer . 2000;  82 1967-1973
    CrossrefPubMedGoogle Scholar
  • 8 Meehan K, Memoli V, Rousseau S, Zacharski L. Presence of components of the coagulation and fibrinolysis pathways in situ in malignant glioma tissue.  Blood . 1994;  84(Suppl 1, part 1) 679a-679a Abst
    PubMedGoogle Scholar
  • 9 Bardos H, Molnar P, Csecsei G, Adany R. Fibrin deposition in primary and metastatic human brain tumors.  Blood Coagul Fibrinolysis . 1996;  7 536-548
    PubMedGoogle Scholar
  • 10 Heesen M, Kemkes-Matthes B, Deinsberger W, Boldt J, Matthes K. Coagulation alterations in patients undergoing elective craniotomy.  Surg Neurol . 1997;  47 35-38
    PubMedGoogle Scholar
  • 11 Fujii Y, Tanaka R, Takeuchi S. Serial changes in hemostasis after intracranial surgery.  Neurosurgery . 1994;  35 26-33
    PubMedGoogle Scholar
  • 12 Sawaya R, Auccarello M, Elkaliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part 1. Clinical profile.  J Neurooncol . 1992;  14 119-125
    PubMedGoogle Scholar
  • 13 Quevedo J, Buckner J, Schmidt J, Dinapoli R, O'Fallon J. Thromboembolism in patients with high-grade glioma.  Mayo Clin Proc . 1994;  69 329-332
    CrossrefPubMedGoogle Scholar
  • 14 Brandes A, Scelzi E, Salmistraro G. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study.  Eur J Cancer . 1997;  33 1592-1596
    CrossrefPubMedGoogle Scholar
  • 15 Anderson F, Huang W, Sullivan C, Hochberg F, Hartman L. The continuing risk of venous thromboembolism following operation for glioma: findings from the glioma outcomes project.  Thromb Haemost . 2001;  Suppl OC902-OC902 Abst
    PubMedGoogle Scholar
  • 16 Dhami M, Bona R, Calogero J, Hellman R. Venous thromboembolism and high grade gliomas.  Thromb Haemost . 1993;  70 393-396
    PubMedGoogle Scholar
  • 17 Nurmohamed M, van Riel A, Henkens C. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.  Thromb Haemost . 1996;  75 233-238
    PubMedGoogle Scholar
  • 18 Agnelli G, Piovella F, Buoncristiani P. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.  N Engl J Med . 1998;  339 80-85
    CrossrefPubMedGoogle Scholar
  • 19 Ornstein D, Zacharski L. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.  Int J Hematol . 2001;  73 157-161
    PubMedGoogle Scholar
  • 20 Kaufmann R, Patt S, Schafberg H. Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells.  Neuroreport . 1998;  9 709-712
    PubMedGoogle Scholar
  • 21 Ogiichi T, Hirashima Y, Nakamura S. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.  J Neurooncol . 2000;  46 1-9
    CrossrefPubMedGoogle Scholar
  • 22 Valenzuela R, Shainoff J, DiBello P. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas.  Am J Pathol . 1992;  141 861-880
    PubMedGoogle Scholar
  • 23 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin.  Mol Immunol . 1984;  21 89-94
    CrossrefPubMedGoogle Scholar
  • 24 Ruf W, Mueller B. Tissue factor signalling.  Thromb Haemost . 1999;  82 175-182
    PubMedGoogle Scholar
  • 25 Bromberg M, Konigsberg W, Madison J, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.  Proc Natl Acad Sci USA . 1995;  92 8205-8209
    Google Scholar
  • 26 Fischer E, Riewald M, Huang H-Y. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.  J Clin Invest . 1999;  104 1213-1221
    Google Scholar
  • 27 Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis.  Curr Opin Hematol . 1996;  3 379-384
    CrossrefPubMedGoogle Scholar
  • 28 Abe K, Shoji M, Chen J. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.  Proc Natl Acad Sci USA . 1999;  96 8663-8668
    Google Scholar
  • 29 Berkman R, Merrill M, Reinhold W. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.  J Clin Invest . 1993;  91 153-159
    CrossrefPubMedGoogle Scholar
  • 30 Jensen R. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review.  Surg Neurol . 1998;  48 189-196
    PubMedGoogle Scholar
  • 31 Schiff D, DeAngelis L. Therapy of venous thromboembolism in patients with brain metastases.  Cancer . 1994;  73 493-498
    CrossrefPubMedGoogle Scholar
  • 32 Bona R, Hickey A, Wallace D. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis.  Am J Clin Oncol . 2000;  23 71-73
    CrossrefPubMedGoogle Scholar
  • 33 Hutten B, Prins M, Gent M. Incidence of recurrent thromboembolism and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis.  J Clin Oncol . 2000;  18 3078-3083
    PubMedGoogle Scholar
  • 34 Ornstein D, Zacharski L. The use of heparin for treating human malignancies.  Haemostasis . 1999;  29(Suppl S1) 48-60
    CrossrefPubMedGoogle Scholar
  • 35 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  Am J Med . 1996;  100 269-277
    CrossrefPubMedGoogle Scholar
  • 36 Gould M, Dembitzer A, Sanders G, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.  Ann Intern Med . 1999;  130 789-799
    PubMedGoogle Scholar
  • 37 Hettiarachchi R, Smorenburg S, Ginsberg J. Do heparins do more than just treat thrombosis?.  <~>The influence of heparins on cancer spread. Thromb Haemost . 1999;  82 947-952
    PubMedGoogle Scholar
  • 38 Lensing A, Prins M, Davidson B, Hirsh J. Treatment of deep venous thrombosis with low-molecular weight heparins. A meta-analysis.  Arch Intern Med . 1995;  1995 601-607
    PubMedGoogle Scholar
  • 39 Turpie A, Gallus A, Hoek J. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med . 2001;  344 619-625
    CrossrefPubMedGoogle Scholar
  • 40 Eriksson B, Ogren M, Agnelli G. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement.  Thromb Haemost . 2001;  Suppl OC1638-OC1638 Abst
    PubMedGoogle Scholar
  • 41 Eriksson H, Wahlander K, Gustafsson D. Efficacy and tolerability of the novel, oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), compared with standard therapy for the treatment of acute deep vein thrombosis.  Thromb Haemost . 2001;  Suppl OC2348-OC2348 Abst
    PubMedGoogle Scholar
  • 42 Francis C, Davidson D, Berkowitz S. Randomized, double-blind, comparative study of ximelagatran (pINN, formerly 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA).  Thromb Haemost . 2001;  Suppl OC44-OC44
    PubMedGoogle Scholar
  • 43 Bergqvist D, Holmdahl L, Solhaug J-H, Eriksson U. Efficacy and safety of subcutaneous melagatran and oral ximelagatran (pINN, formerly H 376/95) as prophylaxis against thromboembolic complications following general abdominal surgery.  Thromb Haemost . 2001;  Suppl OC1020-OC1020 Abst
    PubMedGoogle Scholar
  • 44 Ishibashi H, Nakagawa K, Onimaru M. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities.  Cancer Res . 2000;  60 6531-6536
    PubMedGoogle Scholar
  • 45 Bajaj M, Bajaj S. Tissue factor pathway inhibitor: potential therapeutic applications.  Thromb Haemost . 1997;  78 471-477
    PubMedGoogle Scholar
  • 46 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.  Crit Care Med . 2000;  28(Suppl) S31-S33
    Google Scholar
  • 47 Amirkhosravi A, Meyer T, Chang J-Y. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma.  Blood . 2000;  96(Part 1) 565a-565a Abst
    PubMedGoogle Scholar
  • 48 }Ferro D, Basili S, Pratico D. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients.  Blood . 1999;  93 2945-2950
    PubMedGoogle Scholar
  • 49 Holschermann H, Kohl O, Maus U. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients.  Circulation . 1997;  96 4232-4238
    PubMedGoogle Scholar
  • 50 Susen S, Hazzan M, Labalette M. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications.  Thromb Haemost . 2000;  84 764-769
    PubMedGoogle Scholar
  • 51 Amirkhosravi A, Meyer T, Warnes G. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor.  Thromb Haemost . 1998;  80 598-602
    PubMedGoogle Scholar
  • 52 Falanga A, Consonni R, Marchetti M. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.  Blood . 1998;  92 143-151
    PubMedGoogle Scholar
  • 53 Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3.  Semin Thromb Hemost . 1998;  24 217-226
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Tenno T, Oberg F, Nilsson K, Siegbahn A. Induction of differentiation in U-937 and NB4 cells is associated with inhibition of tissue factor production.  Eur J Haematol . 1999;  63 112-119
    PubMedGoogle Scholar
  • 55 Falanga A, Iacoviello L, Evangelista V. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid.  Blood . 1995;  86 1072-1081
    PubMedGoogle Scholar
  • 56 DiSanto A, Napoleone E, Donati M, Lorenzet R. Angiotensin II upregulates tissue factor expression by human monocytes.  Thromb Haemost . 2001;  Suppl OC215-OC215 Abst
    PubMedGoogle Scholar
  • 57 Napoleone E, DiSanto A, Donati M, Lorenzet R. Renin-angiotensin blockade downregulates tissue factor expression by human endothelial cells.  Thromb Haemost . 2001;  Suppl OC62-OC62 Abst
    PubMedGoogle Scholar
  • 58 Corseaux D, Ollivier V, Fontaine V. Hemostasis imbalance in experimental hypertension. Prevention by zofenopril.  Thromb Haemost . 2001;  Suppl OC1024-OC1024 Abst
    PubMedGoogle Scholar
  • 59 Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins.  Ann Intern Med . 2000;  32 164-176
    PubMedGoogle Scholar
  • 60 Bouterfa H, Sattelmeyer V, Czub S. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.  Anticancer Res . 2000;  20 2761-2772
    PubMedGoogle Scholar
  • 61 Feleszko W, Balkowiec E, Sieberth E. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.  Int J Cancer . 1999;  81 560-567
    CrossrefPubMedGoogle Scholar
  • 62 Kikuchi T, Nagata Y, Abe T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.  J Neurooncol . 1997;  34 233-239
    CrossrefPubMedGoogle Scholar
  • 63 Macaulay R, Wang W, Dimitroulakos J, Becker L, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.  J Neurooncol . 1999;  42 1-11
    CrossrefPubMedGoogle Scholar
  • 64 Ray J, Mamdani M, Tsuyuki R. Use of statins and the subsequent development of deep vein thrombosis.  Arch Intern Med . 2001;  161 1405-1410
    CrossrefPubMedGoogle Scholar
  • 65 Rosenson R, Tangney C. Antiatherothrombotic properties of statins.  JAMA . 1998;  279 1643-1650
    CrossrefPubMedGoogle Scholar
  • 66 Musial J, Undas A, Dreger B, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin lowers thrombin generation and C-reactive protein (CRP) in patients with ischemic heart disease (IHD) and borderline-high cholesterol levels.  Thromb Haemost . 1999;  Suppl 728-728 Abst
    PubMedGoogle Scholar
  • 67 Colli S, Lalli M, Eligini S. Vastatins inhibit tissue factor expression by human macrophages.  Thromb Haemost . 1997;  Suppl 199-199 Abst
    PubMedGoogle Scholar
  • 68 Allessandri C, Ferro D, Basilim S. Simvastatin reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia.  Thromb Haemost . 1997;  Suppl 206-206 Abst
    PubMedGoogle Scholar
  • 69 Soma M, Baetta R, Renzis M D. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.  Cancer Res . 1995;  55 597-602
    PubMedGoogle Scholar
  • 70 Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.  J Neurochem . 1996;  66 710-716
    PubMedGoogle Scholar
  • 71 Ornstein D, Dixon P, McGlasson D. Lovastatin inhibits tissue factor expression by cultured human melanoma cells- a possible explanation for antineoplastic activity.  Thromb Haemost . 2001;  Suppl P566-P566 Abst
    PubMedGoogle Scholar
  • 72 Thibault A, Samid D, Tompkins A. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.  Clin Cancer Res . 1996;  2 483-491
    PubMedGoogle Scholar
  • 73 Larner J, Jane J, Laws E. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme.  Am J Clin Oncol (CCT) . 1998;  21 579-583
    CrossrefPubMedGoogle Scholar
  • 74 Splichal J, Ornstein D, Hong-Dice Y, Downs J, Fischer J. Lovastatin for the prevention of melanoma: analysis of AFCAPS/TexCAPS.  Proc Am Soc Clin Oncol . 2001;  20 351a-351a Abst
    PubMedGoogle Scholar
  • 75 Ornstein D, Zacharski L, Memoli V. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.  Cancer . 1991;  68 1061-1067
    PubMedGoogle Scholar
  • 76 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M. Specificity of a monoclonal antibody for the NH2-terminal fragments derived from fibrinogen and fibrin.  Mol Immunol . 1983;  20 1191-2000
    CrossrefPubMedGoogle Scholar
      >